Journal of thrombosis and haemostasis : JTH
-
J. Thromb. Haemost. · May 2018
Multicenter Study Observational StudyLow drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
Essentials Direct oral anticoagulants (DOACs) do not require laboratory monitoring currently. DOAC specific measurements were performed at trough in patients with atrial fibrillation. Patients who developed thromboembolic events showed lower DOAC plasma levels. This study supports the concept of measuring DOAC levels at steady state.
-
J. Thromb. Haemost. · Nov 2017
Multicenter Study Observational StudyClinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow-up study.
Essentials Late sequelae of isolated superficial vein thrombosis (iSVT) have rarely been investigated. We studied 411 consecutive outpatients with acute iSVT with a median follow-up of three years. Male sex and cancer are risk factors for future deep vein thrombosis or pulmonary embolism. Patients without cancer appear to be at a negligible risk for death.
-
J. Thromb. Haemost. · Nov 2017
Randomized Controlled Trial Multicenter Study Comparative StudyEffect of late prophylaxis in hemophilia on joint status: a randomized trial.
Essentials High-quality data are lacking on use of prophylaxis in adults with hemophilia and arthropathy. SPINART was a 3-year randomized clinical trial of late/tertiary prophylaxis vs on-demand therapy. Prophylaxis improved function, quality of life, activity and pain but not joint structure by MRI. Prophylaxis improves function but must start before joint bleeding onset to prevent arthropathy.
-
J. Thromb. Haemost. · Aug 2017
Multicenter StudySafety of multidetector computed tomography pulmonary angiography to exclude pulmonary embolism in patients with a likely pretest clinical probability.
Essentials Safety of computed tomography (CTPA) to exclude pulmonary embolism (PE) in all patients is debated. We analysed the outcome of PE-likely outpatients left untreated after negative CTPA alone. The 3-month venous thromboembolic risk in these patients was very low (0.6%; 95% CI 0.2-2.3). Multidetector CTPA alone safely excludes PE in patients with likely clinical probability.
-
J. Thromb. Haemost. · Aug 2017
Multicenter StudyAccuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
Essentials Accurate determination of anticoagulant plasma concentration is important in clinical practice. We studied the accuracy and consistency of anti-Xa assays for rivaroxaban in a multicentre study. In a range between 50 and 200 μg L-1 , anti-Xa activity correlated well with plasma concentrations. The clinical value might be limited by overestimation and intra- and inter-individual variation.